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Oxidative damageNeuroferritinopathy is a rare, late-onset, dominantly inherited movement disorder caused by mutations in
L-ferritin gene. It is characterized by iron and ferritin aggregate accumulation in brain, normal or low serum
ferritin levels and high variable clinical feature. To date, nine causative mutations have been identiﬁed and
eight of them are frameshift mutations determined by nucleotide(s) insertion in the exon 4 of L-ferritin gene
altering the structural conformation of the C-terminus of the L-ferritin subunit. Acting in a dominant negative
manner, mutations are responsible for an impairment of the iron storage efﬁciency of ferritin molecule. Here,
we review the main characteristics of neuroferritinopathy and present a computational analysis of some
representative recently deﬁned mutations with the purpose to gain new information about the pathogenetic
mechanism of the disorder. This is particularly important as neuroferritinopathy can be considered an interesting
model to study the relationship between iron, oxidative stress and neurodegeneration.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).ContentsNeuroferritinopathy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 134
Genetics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 135
Clinical features . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 136
Diagnosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 136
Pathology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 137
Ferritin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 137
Neuroferritinopathy variants . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 138
Advancement on pathogenetic mechanism studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 139
In vitro studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 139
Cellular models . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 140
Fibroblasts from a patient carrying the c.497_498dupTC mutation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 141
Animal models . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 141
Proposed pathogenetic mechanisms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 141
Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 142
Acknowledgments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 142
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 142ghtchaingene;FtL, Ferritin light
nic;WT,wild type;ROS, reactive
University, and San Raffaele
ax: +39 02 26434844.
ect.com).
. This is an open access article underNeuroferritinopathy
The Neuroferritinopathy (NF) (OMIM, 606159, also labeled as
hereditary ferritinopathies or NBIA3) (Curtis et al., 2001; Ohta and
Takiyama, 2012) is a rare monogenic autosomal-dominant disease
caused by mutations in the gene encoding the ferritin L-chain (FTL1)the CC BY license (http://creativecommons.org/licenses/by/4.0/).
135S. Levi, E. Rovida / Neurobiology of Disease 81 (2015) 134–143one of the two subunits of the main iron storage protein. The disease is
classiﬁed as belonging to a growing collection of movement disorders
named Neurodegeneration with Brain Iron Accumulation (NBIA). The
NBIA are a group of degenerative extrapyramidal monogenic genetic
diseases determining, in affected patients, radiological evidence of
focal accumulation of iron in the brain, usually in the basal ganglia.
They are characterized by early- or late onset with main symptoms
that are problems encountered in the movement, spasticity and cogni-
tive deﬁcits (Levi and Finazzi, 2014). Among the causative genes, it
can be distinguished between those encoding proteins directly involved
in iron metabolism (FTL1 and CP) and those encoding proteins respon-
sible for other functions, such as: i) fatty acid metabolism and other
mitochondrial functions (PANK2, PLA2G6, C19orf12, COASY, and FA2H
genes); ii) lysosomal and autophagosome activity (WDR45 and
ATP13A2 genes); and iii) a nuclear protein of still unknown function
(C2orf37 gene) (for an extensive review see Levi and Finazzi, 2014). A
small subgroup of the identiﬁed NBIA cases is represented by NF,
which is the only form inherited in an autosomal dominant manner.
From an epidemiological point of view, it is important to note that
this disorder is extremely rare, thus so far, there is no available data
on the prevalence of the disease in the population. However, due to
overlapping of symptoms and MRI signs with the other forms of NBIA,
it is conceivable that other incorrectly diagnosed cases may exist.
Genetics
NF was initially identiﬁed by Curtis among the members of a large
family from the Cumbrian region of North England (Curtis et al.,
2001). Using a genome wide linkage analysis, the authors identiﬁed
the insertion of an adenine in position c.460 of exon 4 of the FTL1 gene
as the causativemutation of a previously unacknowledged neurodegen-
erative disorder that they named neuroferritinopathy (Curtis et al.,
2001). Initially, the disease appeared to be conﬁned to the population
of North England, where more than 40 cases with the same mutation
were identiﬁed, suggesting that they originated from a commonTable 1
List of reported cases and related mutations of neuroferritinopathy.
Families from: DNAa mutations Protein variantb Symptomatology
Cumbrian region (UK) c.460dupA p.Arg154LysfsX27 Extrapyramidal dysfunctio
choreathetosis, dystonia, s
Northwest of UK c.460dupA p.Arg154LysfsX27 Extrapyramidal dysfunctio
France c.460dupA p.Arg154LysfsX27 Dystonia, dysarthria, chore
North of UK c.460dupA p.Arg154LysfsX27 Extrapyramidal dysfunct
South of UK c.460dupA p.Arg154LysfsX27 Generalized dystonia, ps
France c.497_498dup p.Phe167SerfsX26 Tremor, cerebellar ataxia
disturbances, cognitive d
Gypsy ancestry c.285G N A p.Ala96Thr Parkinsonism, ataxia, and
French Canadian and
Dutch ancestry
c.442dupC p.His148ProfsX33 Dystonia, dysarthria, cho
mitochondrial respirator
Japan c.469_484dup p.Leu162ArgfsX24 Tremor, hypotonia, hypere
France c.458dupA p.His153GlnfsX28 Dystonia, dysarthria, dys
Japan c.439_442dup p.His148ArgfsX34 Chorea, tremor, dyskines
Italy c.469_484dup p.Leu162ArgfsX24 Axial ataxia, severe dysart
Japan c.468_483dup p.Leu162TrpfsX24 Chronic headache, orolin
pyramidal tract signs, ps
France c.468dupT p.Gly157TrpfsX24 Dystonia, dysarthria, dys
DNA mutations (a) and protein variants (b) are named according to the HGVS nomenclature
database entry 33070.1.
c: Serum ferritin values were reported in μg/L, in brackets the reference ranges for normal indi
N.R. = not reported, Normal = value in normal range.founder (Chinnery et al., 2007). Subsequently, other cases were
described in different parts of the world. Up to now, other 8 types of
mutations have been identiﬁed in different ethnic groups (Vidal et al.,
2003); (Mancuso et al., 2005);(Maciel et al., 2005); (Ohta et al.,
2008); (Kubota et al., 2009); (Devos et al., 2009; Moutton et al., 2014;
Nishida et al., 2014; Storti et al., 2013); they are reported in Table 1,
adopting the HGVS nomenclature (den Dunnen and Antonarakis, 2000
and www.hgvs.org/mutnomen). The FTL1 gene is located on chromo-
some 19q13.33 and it is composed by 4 exons and 3 introns. All the
NF causative mutations, except one, are located on the exon 4 of the
gene in a short DNA fragment of 58 nucleotides in length. They are
single or multiple (from 2 to 16) nucleotides resulting in an altered
sequence and length of the C-terminal portion of the encoded protein
(Fig. 1). Interestingly, the mutation c.469_484dup, involving the dupli-
cation of 16 nucleotides, has been identiﬁed in two patients belonging
to different and geographically distant ethnic groups, i.e. Japan (Ohta
et al., 2008) and Italy (Storti et al., 2013). Together, all these observa-
tions insinuate that exon 4 of the FTL1might be recognized as a muta-
tion hotspot. It must be noted that another region of about 70 nts in
length characterized by high mutation frequency was identiﬁed in
FTL1 (Ferrari et al., 2006); (Luscieti et al., 2013). The region is located
at 5′ UTR of the L-ferritin mRNA, corresponding to the iron responsive
element sequence (IRE). It folds in a stem loop structure, and is involved
in the iron-mediated post-trascriptional regulation of ferritin
expression (Hentze et al., 2010). Anomalies in IRE sequence cause a
disease named hereditary hyperferritinemia cataract syndrome
(HHCS, OMIM# 600886). It is a rare autosomal dominant disease
characterized by increased serum ferritin levels and early onset of bilat-
eral cataract (Girelli et al., 1995). Affected individuals show high serum
ferritin levels, with normal serum iron and transferrin saturation, and
without signs of systemic or brain iron overload (Cazzola, 2002). The
lack of post-transcriptional control of ferritin expression produces
L-ferritin (FtL) accumulation in lens, where it induces cataract formation
by altering the delicate equilibrium between other water-soluble
proteins, such as crystallins (Levi et al., 1998).Serum
ferritinc
References
n
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hria, dystonia, bilateral hand tremor, parkinsonism 3
(17–400)
Storti et al. (2013)
gual dystonia, disarthria, cerebellar ataxia,
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Nishida et al. (2014)
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guidelines (den Dunnen 2000). Nucleotides and aminoacid numbers correspond to CCDS
viduals,
Fig. 1. Schematic representation of L ferritin secondary structure and sequence alignment of FtL andNF variants. Human L ferritin sequence ismatchedwith a schematic diagramof protein
secondary structure elements that include ﬁve α-helices segments (red in upper ﬁgure), conventionally named with letters from A to E, connected by four loop elements and of two
additional loops at the N and C termini (shown in blue). The red circlemarks the position of residue 96, mutated in the uniquemissense variant (p.Ala96Thr). The blue rectangle highlight
the sequence interval, from residue 148 to 175, involved in the so far detected frameshift variants. Frameshiftmutations observed inpatients are responsible for aminoacidic changes at the
C-terminus starting from different sequence position depending on the duplication starting point. In panel B the alignment of the frameshift altered regions compared with the wild type
FtL sequence is shown. Dashes correspond to unchanged position while modiﬁed residues are underlined.
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generative disorders, such as Parkinson's (PD) and Alzheimer's disease
(AD). There are some controversies in the literature regarding the
change in the concentration of ferritin in PD brain compared to controls,
while an increase in brain ferritin amount in AD is well accepted (for a
in-depth discussion on this topic see (Finazzi and Arosio, 2014)).
Nevertheless, abnormal ferritin levels in PD and AD are associated to a
loss of ferritin ability to maintain iron homeostasis (Finazzi and
Arosio, 2014);(Connor et al., 1995) rather than a sequence variation of
ferritin genes as in NF.
Clinical features
So far, the largest cohort of NF patients was analyzed by Chinnery
and coworkers (Chinnery et al., 2007). The authors collected data on
41 patients, all of them carrying the c.460dupA mutation, and showing
an average age of onset of 39.4 years. The main clinical manifestations
were those that characterized extrapyramidal disorders: chorea (50%),
followed by focal lower limb dystonia (42.5%) and parkinsonism
(7, 5%). Patients often showed typical facial anomalies due to the activa-
tion of the frontal muscles, in particular oromandibular dyskinesia. In
general, there was asymmetry throughout the disease course: the early
signs could disturb the ﬁrst one side of the body and then the other, or
they were intermittent. Progression was slow and eventually leading to
aphonia, dysphagia and severe motor disability with subcortical/frontal
cognitive dysfunction as a late feature (Chinnery et al., 2007).
Comparison of clinical evidences in patients carrying other muta-
tions showed that all of them gave rise to similar symptoms, such as
oro-buccal dyskinesia, chorea and dystonia. However, subtle phenotyp-
ic variations between them in terms of age of onset, progression of the
disease or the presence of cognitive disorders were observed (Table 1)
(for a full description of all cases see Keogh et al., 2013). Indeed, a recent
study reported a new case with atypical presentation (Nishida et al.,
2014). The authors described a family affected by chronic headaches
and lacking the classical clinical symptoms at the early stage of the dis-
ease; however they developed progressive orolingual and arm dystonia,
dysarthria, cerebellar ataxia, pyramidal tract signs, and psychiatric
symptoms in a later stage (Nishida et al., 2014). Thus, it is conceivablethat the disease can manifest with a variety of symptoms that have
not yet been fully described.
Diagnosis
Routine blood tests are usually normal in patients, except for serum
ferritin, which is often lower than normal (Table 1) and thus can be a
warning sign when the presence of disease is suspected. Lehn et al.
(2012) reviewed all the published NF cases and calculated that 64% of af-
fected males and 84% of females exhibited levels of serum ferritin lower
than a cutoff value set to 30 g/L. Analysis of cerebrospinal ﬂuid (CSF)
did not show appreciable differences (Chinnery et al., 2007); (Wills
et al., 2002; Lehn et al., 2012). However, the case described by Nishida
et al. (2014) showed a remarkably low level of CSF ferritin (b1 ng/ml),
compared to values of control subjects (6.68+/−0.93 ng/ml), and
despite a ferritin level of 20 g/L in serum.
Standard histochemical analyses of muscle biopsies are usually
normal; however Chinnery et al. (2007) found a signiﬁcant percentage
of cytochrome c oxidase-negative ﬁbers in 2 out of 9 analyzed patients,
in addition to isolated or combined defects of respiratory chain
complexes in 5 out of 6 analyzed patients.
Magnetic Resonance Imaging (MRI) is the most effective tool for NF
diagnosis (see an example in Fig. 2); it is applicable during the whole
course of the disease, with important detections also in the early stages.
In fact, iron deposits in cerebellum, basal ganglia and motor cortex are
detected by traditional “gradient echo sequences” (T2*), although
more recently the “susceptibility weighted imaging” (SWI) is emerging
as a viable alternative.
The ﬁrst visible MRI change in early stage symptomatic, and also in
some asymptomatic carriers, is a hypodensity in T2* and SWI at the
level of the dentate nucleus, red nucleus, substantia nigra, putamen,
globus pallidus, thalamus, caudate nucleus and the motor cortex
(Chinnery et al., 2007); (Ohta and Takiyama, 2012). In this phase, the
only visible abnormality in T2-weighted images is a slight lowering of
the level signal of the nuclei of the base (Chinnery et al., 2007). With
the progression of the disease, the T2-weighted images showed
hyperintensity at the level of the basal ganglia due to edema and gliosis
prior to degeneration (Chinnery et al., 2007); (Ohta and Takiyama,
Fig. 2.BrainMRI inNeuroferritinopathy. BrainMR images of a Japaneseman carrying the FTL1 c469_484dupmutation. Axial section at the level of the basal ganglia in thepatient at 35 years
of age. A A T1-weighted image (TR 400 msec/ TE 14 msec) shows symmetrical hypointense signals in the head of the caudate nucleus and globus pallidus. B A T2-weighted image
(TR 800 msec/TE 30msec) shows hypointense changes in the lenticular nucleus. Hyperintense signals can be observed in the putamen and the head of the caudate nucleus. Reproduced
from Ohta E, Takiyama Y. MRI ﬁndings in neuroferritinopathy. Neurol Res Int. 2012;2012:197438.
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hyperintensity, due to the deposition of iron (Kruer and Boddaert,
2012). In more advanced stages, areas of cystic cavitation are formed,
which may be preceded by hyperintensity on T1-weighted images,
particularly in the putamen and globus pallidus; these may be associated
with cerebellar atrophy and a slight cerebral atrophy (Kruer and
Boddaert, 2012). However, since “the eye of tiger sign”, which is consid-
ered pathognomonic of PKAN disease, was detected in three NF patients
(McNeill et al., 2008), it must be considered that MRI analysis cannot be
exhaustive and that the diagnostic evidence should always come from
genetic testing.Pathology
The typical neuropathological features of the disease are related to
the presence of ferritin and iron aggregates in neural tissue. Theﬁrst his-
topathology data were reported for patients carrying the c.460dupA
mutation (Curtis et al., 2001). The post-mortem brain inspection
revealed the presence of spherical granules in the globus pallidus,
forebrain and cerebellum. These granules were positive for both iron
and ferritin staining. They were mainly extracellular but co-localized
also within neurons, oligodendrocytes and microglia. Subsequent
brain histopathological analysis of patients carrying c.442dupC and c.
497_498dupTC mutations (Vidal et al., 2004); (Mancuso et al., 2005)
conﬁrmed that the presence of intracytoplasmic and intranuclear aggre-
gates of ferritin in the glial cells and in someneuronal subtypes, deposits
of iron, gliosis and neuronal death represented the prevalent neuro-
pathological ﬁndings in NF. In general neuronal aggregates were
observed in putamen, globus pallidus, thalamus, in cerebellar granule
and Purkinje cells, while glial cell aggregates were mainly detected in
the caudate, putamen and globus pallidus. In these patients, the compo-
sition of aggregates was determined by immunostaining with anti-wild
type FtL, anti-variant FtL and anti FtH antibodies (Vidal et al., 2004),
suggesting that the three ferritins species were assembled in the full
ferritin 24-mer. They also contained both Fe2+ and Fe3+, as revealed
by Turnbull and Perls' Prussian blue staining, respectively (Mancuso
et al., 2005). The presence of aggregates was detected not only in
CNS but also in other tissues such as skin, liver, kidney and muscle
(Mancuso et al., 2005; Vidal et al., 2004).Ferritin
Ferritin is the ubiquitous protein of iron storage, evolutionary con-
served from prokaryotes to mammals; it is characterized by a structure
evocative of its function, consisting of a virtually spherical shell with an
internal cavity that can accommodate up to 4500 iron atoms (Arosio
and Levi, 2010). Its primary functional role is to sequester free iron
from various cell compartments preventing its reaction with oxygen
and the consequent formation of reactive oxygen species (ROS) whose
oxidative harmful effect are well known (Graf et al., 1984). For this
reason, ferritin is widely distributed in different tissues and cell
compartments. Cytoplasmatic ferritin is most abundant in human cells
(Arosio and Levi, 2010), however a mitochondrial form has also been
identiﬁed and characterized (Levi et al., 2001). Cytosolic ferritin has a typ-
ical quaternary structure symmetrically assembled fromof 24 subunits of
two different types, termed H and L (Fig. 3B-C-D), which are present in
different proportions depending on tissue type (Arosio and Levi, 2010).
The H and L chains are encoded by human genes, located on chromo-
somes 11 and 19, respectively, and share about 55% amino acid sequence
identity. The 3D structure of the two chains is very similar: a bundle of 4
helices, with a long loop that connects the helix B and helix C, and a ﬁfth
smaller helix called E at the C-terminus, which forms an angle of 60° re-
spect to the bundle of 4 helices, and is directed towards the center of the
cavity (Fig. 3A). The H chain has a ferroxidase center within the bundle,
where the oxidation of iron occurs (Levi et al., 1988); (Lawson et al.,
1991) (Fig. 3A, left panel). Most of residues in the H chain that create
the binding site for the iron are different in the L chain and create a
salt bridge that stabilizes the chain (Santambrogio et al., 1992)
(Fig. 3A, panel right). The L chain facilitates the mineralization of the
iron in the cavity supporting the ferroxidase activity of the H chain
(Levi et al., 1994), in fact, both in vitro and in vivo studies demonstrated
that heteropolymers of the two subunits incorporates iron more efﬁ-
ciently than the homopolymers (Levi et al., 1994). The iron enters in
the cavity through eight channels formed by the hydrophilic helices C
and D of 3 different subunits, along the 3-fold symmetry axis (Fig. 3C),
which have a binding site for metals; through these channels, individual
iron atoms can diffuse in and out of ferritin (Watt et al., 2010). In
addition to the hydrophilic channel there is another type of channel,
along the 4-fold axis, formed by helices E of 4 different subunits, with
hydrophobic properties because rich in leucine residues (Fig. 3D). The
Fig. 3. Three-dimensional structure of ferritin. Ferritin subunit is a four-helix bundle protein consisting of two couples of anti-parallel α-helices (A–B and C–D) connected by a long loop
and a short C-terminalα-helix (E) important for 24-mer stabilization. Human L and H ferritin subunits share a 55% sequence identity and a remarkably similar 3D structure. A In central
panel is shown a ribbon representation of superposed L (blue) and H (red) human ferritin subunits. Superposition of the two structures yielded a root mean square deviation (RMSD) of
0.5 Å, indicating an elevated level of structural similarity. The two subunits show a different residue arrangement in the center of four-helix bundle, corresponding to the blue box. Arrows
departing from the box point to the expanded representation of the region in H-chain (panel left side) and L-chain (panel right side). In H chain, a ferroxidase center is formed by a set of
iron coordinating residues,which are replaced by a salt bridge forming amino acids in the L chain. The functional protein is a 24-mer polymermade of variable proportion of H and L chains
that assemble following a two-three- and four-fold symmetry. The assembled ferritin appears as a hollow spherical shell (panel B). Subunit interactions in the 24-mer generate 12 dimeric
interfaces (a dimer formed by one H and one L chain is shown as an example in panel B), eight hydrophilic channels, each obtained from 3 subunits, at the three fold axes (panel C) and six
hydrophobic channels, obtained from 4 subunits at the four-fold axes (panel D). Structureswere obtained from Protein Data Bank (PDB code: 2FFX for L- chain, 1FHA for H-chain; Berman
et al, 2000).
138 S. Levi, E. Rovida / Neurobiology of Disease 81 (2015) 134–143calculation of the local electrostatic potential suggests that this channel
may be involved in the outﬂow of protons that occurs following the
incorporation of iron into the cavity (Douglas and Ripoll, 1998).
Neuroferritinopathy variants
Among the nine FtL variants identiﬁed so far, there is only a single
case of a missense mutation (p.Ala69Thr), while all the others are
responsible for a frameshift at C-terminus of the L chain resulting in a par-
tial or complete sequence change of the E-helix (Table 1 and Fig. 1). Var-
iants can be roughly divided into two groups: 1) the frameshift is
upstream of the loop connecting D-helix to E-helix, thus the aminoacidic
changes involve a long sequence stretch (26 to 33 residues) but the total
protein length is similar to wild type (the ﬁrst 5 variants in Fig. 1) and 2)
the frameshift is downstreamof the loop (variants 6 to 8 in Fig. 1) and the
sequence length is from 8 to16 residues longer than wild type.
Between them, the variant p.Phe167SerfsX26 is best characterized at
a biochemical and structural level (Baraibar et al., 2008);(Luscieti et al.,
2010). X-ray crystal structure of the mutated monomer revealed the
ferritin typical four helix bundle fold but missing the C-terminal
E-helix that could not be solved due to the disorder and/or instabilityof the mutated peptide replacing the C-terminal helix (Luscieti et al.,
2010). This has a deleterious effect on the 4 fold channel geometry
and permeability, leading to mishandling of iron in ferritin. The struc-
tural effect of this mutation is depicted in Fig. 4, where the molecular
surface of different types of tetramers within the ferritin 24-mer is
shown. The wild type 4 fold channel (Fig. 4A) formed by four wild
type subunits (FtH chains in red and FtL chains in blue) appears tightly
packed and closed due to the presence of an arrangement of hydropho-
bic residues. A fully mutated tetramer instead (Fig. 4B) opens up a large
pore at the four-fold channel, about 14 Åwide, dramatically altering the
iron permeability of the ferritin shell. In these patients two different L
chain alleles (wild type and mutated), in addition to the wild type H
chain, are expressed; therefore, mixed heteropolymers including the
three subunit types, are likely to be more representative of the in vivo
condition. Within each 24-mer, the four-fold axis pore can be formed
by different combinations of the variant FtL with the wild type L and
H subunits (Fig. 4C-D-E). As depicted in Fig. 4, the pore width increases
proportionally to the number of variant FtL chains participating in the
tetramer assembly (cyan in Fig. 4). It is therefore apparent that even a
small amount of mutant incorporation will affect iron management
ability of the protein.
Fig. 4.Molecular surface representation of ferritin subunits forming the 4-fold axis hydrophobic pore. A Representative wild type pore formed by two FtL (blue) and two FtH (red) chains.
The wild type channel appears very narrow due to the presence of tightly packed hydrophobic residues. B Putative pore formed by 4 identical FtLPhe167SerfsX26 subunits (cyan). The
opening of the pore is largely increased, altering the iron permeability of the ferritin shell. In patients carrying FtL mutation, two different L chain alleles (wild type and mutated), in
addition to the wild type H chain, are expressed; therefore, mixed heteropolymers are likely to occur. Three putative combinations of FtL (blue), FtH (red) and FtLPhe167SerfsX26
(cyan) subunits, have been reconstructed in panels C, D, and E, increasing the proportion of mutated chain. The pore width increases proportionally to the number of variant chains
participating in the tetramer assembly. (The structure of FtLPhe167SerfsX26 variant was obtained from Protein Data Bank. PDB code: 2KXU).
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frameshift variants (Table 1) can be attributed to a similar structural
and functional impairment. Biochemical characterization of these
variants is made difﬁcult by the instability of the expressed proteins
(Levi, unpublished data). To gain insight into the structural and
functional effects of aforesaid mutations, we applied a predictive com-
putational analysis to three representative variants p.Arg154LysfsX27,
p.His148ProfsX33, p.Leu162ArgfsX24.
Molecular models were obtained by threading approach (Roy et al.,
2010). In all cases, the mutated C-terminal peptides were predicted to
assume a helical conformation superposed to the wild type E helix
and further protruding into the cavity according to the extension of
the C-terminal sequence. Electrostatic potential calculations (Honig
and Nicholls, 1995) were performed for the obtained models and then
represented as surface distribution for reconstructed homo-tetramers
of each variants and for FtL. In Fig. 5 the distribution of the potential
on the inner surface of the assembled protein for the FtL (Fig. 5A) and
for the variants is shown (Fig. 5B-C-D). The prevalence of negative
charges on the FtL (red surface in Fig. 5A) is a requirement for the iron
nucleation inside the cavity. All the analyzed variants show a cluster
of positive charges (blue surface in Fig. 5B-C-D) around the four-fold
channel, that can be responsible for a repulsive effect on iron complex.
In addition, the reconstruction of the four-fold tetramer showed, for
all variants, a loose channel likely to alter the ferritin shell permeability.
Although the modeling of the variant subunits might not reﬂect the
actual state of the protein under physiological conditions, it provides a
key for interpretation of the mutant effect. The change at the subunit
C-terminus implies amodiﬁcation of themicroenvironment of the ferri-
tin cavity that loses its ability to correctly process the iron deposition
and retention. As for the unique missense variant related to NF onset
(p.Ala96Thr) (Maciel et al., 2005), its effect can be hardly explained onthe basis of the structural or functional impairment. In fact the amino
acidic substitution is predicted as tolerated by most reliable methods
of protein mutant prediction such as SIFT (Ng and Henikoff, 2003) and
PolyPhen2 (Adzhubei et al., 2013).
Advancement on pathogenetic mechanism studies
Several in vitro and in vivo studies were performed in an attempt to
understand the pathogenetic mechanism of the disease. Most of
them were carried out on the p.Phe167SerfsX26 variant (referred as
FtLPhe167SerfsX26 in this section) (Fig. 1) as the in vitro stability of the
protein product is higher than for other variants and adequate for
performing biochemical analyses.
In vitro studies
Biochemical study on the aggregates puriﬁed from patient tissues
identiﬁed the presence of all the three subunit types: FtH, FtL and
FtL Phe167SerfsX26 peptides, indicating that the variant peptide is able to
assemble in vivo into the 24-mer molecule (Vidal et al., 2004). Indeed,
the biochemical and crystallographic characterization of the recombi-
nant homopolimer FtLPhe167SerfsX26 showed that it exists as a 24-mer
molecule with an altered conformation of the C-terminus and a large
disruption of the normally tiny four-fold axis pores (Luscieti et al.,
2010); (Baraibar et al., 2010) (Fig. 4). To reproduce the typical form
of ferritin, the authors analyzed in vitro reconstructed ferritin
heteropolymers composed of 20 to 23 H-chains and 4 to 1 either wild
type or variant L-chains (Luscieti et al., 2010). All heteropolymers exhib-
ited a strongly reduced capacity to incorporate iron and a reduced phys-
ical stability. Thus, it was demonstrated that the presence of few
mutated L-chains was sufﬁcient to alter the permeability of 1–2 of the
Fig. 5.Electrostatic potential distributionof the inner surface of homopolymeric 4 fold axis tetramers. The tetrameric assembly of four identical subunitswas reconstructed starting from thewild
type FtL subunit (panel A) and the variants p.Arg154LysfsX27, His148ProfsX33 and His148ProfsX33 (panels B, C, D, respectively). In wild type FtL tetramer (panel A), a prevalence of negative
charges (red surface) is noticeable and is required for the iron nucleation inside the cavity. All the analyzed variants show an increased distribution of neutral or positive charges (white to blue
surface in panels B-C-D) around the four-fold channel, and this can be responsible for a repulsive effect on iron complex. In addition, the reconstruction of the four-fold tetramers showed, for all
variants, awider pore compared towild type, likely to alter the ferritin shell permeability. Thepotential scale ranges from−3kT/e to+3kT/e from red to blue. The PyMolmolecular visualization
system (The PyMOL Molecular Graphics System, Schrödinger, LLC) was used for structure visualization, analysis, comparison and for preparation of images.
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These data highlight the dominant-negative action of the mutations,
which explains the dominant transmission of the disorder (Luscieti
et al., 2010).
Other biochemical studies on FtLPhe167SerfsX26 functionalitywere based
on the in vitro assembly of wt and variant L chains in homopolymeric
form (Baraibar et al., 2010). TEM analysis showed that both homopoly-
mers have spherical structure and dimensions similar to those of
human ferritin (outer diameter approximately 110 Å). Iron incorporation
experiments for the two homopolymers showed a similar functionality at
low iron concentrations (about 1500 iron atoms per 24-mer). When iron
proportion was increased up to 4000 atoms per homopolymer, only the
FtL incorporated iron and remained soluble, while the FtLPhe167SerfsX26
quickly precipitated (Baraibar et al., 2008); (Baraibar et al., 2010). These
results were then conﬁrmed by the same authors for heteropolymers
containing the mutated peptide, which showed a greater propensity to
iron-induced precipitation and reduced functionality (Muhoberac et al.,
2011) compared to FtL. Further studies also reported prominent in vitro
and in vivo propensity of the FtLPhe167SerfsX26 to be oxidized and pointed
out the key role of oxidative stress for NF pathogenesis (Baraibar et al.,
2012).
Cellular models
Cellular models of c.460dupA and c.497_498dupTC were developed
in HeLa and neuroblastoma SH-SY5Y cells by expressing the mutated Lchains under the control of tetracycline (Cozzi et al., 2006); (Cozzi et al.,
2010). Both type of mutations led to same results, suggesting that
similar pathogeneticmechanisms are engaged by different structural al-
terations of ferritin. Both variants were expressed and assembled in the
heteropolymer although at low proportion (an average of less than four
subunits for polymer); their expressionwas associatedwith an increase
of endogenous ferritin chains and a decrease of Transferrin Receptor1
(TfR1) expression. As these parameters aremodulated by iron availabil-
ity in cytosolic compartment, the obtained results clearly indicated the
inefﬁciency of ferritin variants to incorporate iron. The incorporation
of variant peptides in the assembled 24-mer resulted in a reduced ferri-
tin functionality, thus conﬁrming the dominant negative effect of the
mutations (Cozzi et al., 2010). In addition, the containing-altered-
peptide ferritins were degraded much faster than the FtL, primarily via
proteasome, further increasing the iron release in cytoplasm (Cozzi
et al., 2006); (Cozzi et al., 2010). Indeed, an increase of the redox-
active labile iron pool (LIP) was detected after iron treatment, with
consequent enhancement of ROS production after treatment with
H2O2, as well as a defect in the proteasome activity.
Both cell lines developed aggregates, positive to L-ferritin and iron
staining, which grew in number and size after iron addition (Cozzi
et al., 2010). More importantly, these aggregates were not strictly asso-
ciated to cell death: they became evident after 10days of variant expres-
sion and were not associated to cells that were undergoing apoptosis.
The addition of iron chelators or antioxidants restored proteasome ac-
tivity and reduced aggregate formation (Cozzi et al., 2010). Overall
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age were the primary causes of cell mortality, while protein aggregate
formation was a secondary effect.
Fibroblasts from a patient carrying the c.497_498dupTC mutation
Berbeito et al. had the opportunity to analyze skin-derived primary
cells from a NF patient (Barbeito et al., 2010). These cells showed an al-
teredmanagement of iron and ferritin and an accumulation of oxidative
stress markers as it was observed both in patients and in transgenic
mice (Vidal et al., 2008). Under basal conditions, patient's ﬁbroblasts
showed a signiﬁcant increase in the amount of total iron and in the
expression of H-, L- and L-variant ferritin chains compared to control ﬁ-
broblasts. TfR1 expression and the IRE-binding capacity of IRP decreased
consistently with an increase of intracellular free iron, as previously
reported for cellular models. However, signiﬁcant differences in LIP
level were not reported. This apparent discrepancy could be explained
by the fact that even small LIP variations, not precisely detectable by
the common assays, are sufﬁcient to stimulate the iron-mediated
control of protein expression (i.e. TfR1 and ferritins). In addition, the
level of ROS was signiﬁcantly enhanced in NF compared to controls
ﬁbroblasts (Barbeito et al., 2010).
Animal models
A transgenic mouse was obtained by expressing the human cDNA of
FTL1with themutation c.497_498dupTC. The expression of the transgene
in the animal caused the formation of nuclear and cytoplasmic ferritin
aggregates in CNS and other organs (Vidal et al., 2008). Similarly to
patients, the size and the number of nuclear aggregates increased with
the aging of the animal (Vidal et al., 2004). The mouse model showed a
progressive neurological phenotype, decreased mobility and a reduced
life expectancy. In addition, it showed increased amount of iron in the
brain and altered levels of associated proteins: the H and L ferritins ex-
pression was ampliﬁed while TfR1 level decreased. The transgenic
mouse also showed accumulation of oxidized mitochondrial DNA but
no signiﬁcant damage to the nuclear DNA in brain (Deng et al., 2010)
even if markers of oxidative stress such as lipid peroxidation and protein
carbonylation were detected (Barbeito et al., 2009).
Further insight into the NF pathogenetic mechanism was recently
obtained from the characterization of new transgenic mouse models
for the same FTL1mutation. In this work mice models were obtained uti-
lizing a PGK promoter based expression for generation of transgenicmice
in FVB and C57BL/6 J strains (Maccarinelli et al., 2014). FVB transgenic
mice (Tg) showed high accumulation of the FtLPhe167SerfsX26 in brain asso-
ciated with increased iron deposition during age and with signs of oxida-
tive damage. Interestingly, the C57BL/6 Tg mice preserved an evident
oxidative alteration in the brain detectable at 12months of age, although
they showed a reduced FtLPhe167SerfsX26 expression and iron accumulation
compared to the FVB-Tg mice. Ultrastructural analyses of brain tissues
revealed an accumulation of lipofuscin granules associated with iron
deposits, particularly enriched in the cerebellum and striatum of the
C57BL/6 transgenic mice, and localized in cytoplasm. In contrast with
the mouse model described by Vidal et al. (2008), no evidence of the
presence of aggregates in the nucleus and in extracellular compartment
was reported (Maccarinelli et al., 2014). In addition, post-natal hippocam-
pal neurons obtained from C57BL/6 Tg mice showed higher vulnerability
to chronic iron overload and/or acute oxidative stress thenwild-type neu-
rons, indicating amajor propensity to cell death. Furthermore, behavioral
studies showed a progressive impairment in motor coordination of Tg
mice (Maccarinelli et al., 2014).
Proposed pathogenetic mechanisms
The main role of ferritin is exerted by its ability to sequester iron
and keep it in a safe form inside its internal cavity, even though otherfunctions have been recently reported that are not associated with its
metal incorporation activity (reviewed in Finazzi and Arosio, 2014).
Indeed, in the case of NF, overall in vitro and in vivo data, agree in
suggesting a pathogenic mechanism based on the non-controlled
augment of intracytosolic free iron, due to the missing crucial role
of the ferritin in maintaining iron balance inside the cell. In fact, as
conﬁrmed by the molecular modeling data, all the NF causative muta-
tions lead to the same ﬁnal effect: the inefﬁciency of iron nucleation
inside ferritin cavity. This functional impairment can derive both
from an altered arrangement of the residues lining the four-fold hy-
drophobic channel and from a modiﬁcation of the chemico-physical
properties of the ferritin interior which perturb the optimal microen-
vironment for ferrihydrite deposit formation (Behera and Theil,
2014).
Whatever the cause, the unsafely stored iron triggers a cascade of
event leading to a vicious cycle inwhich cytosolic free iron continuously
induces the iron-dependent ferritin mRNA translation, producing three
different subunits (FtH, FtL and variant FtL) that assemble to form ferri-
tinmolecules with a reduced capacity to store iron. In themeantime the
free iron stimulates the formation of ROS, which promote oxidative
damage of cellular components (Cozzi et al., 2010). The overloaded
activity of proteasome system to degrade high levels of oxidized pro-
teins leads to proteasome dysfunction and consequently to ferritin
aggregates formation (Cozzi et al., 2010). In this work, it was also
shown that the proteasome impairment in NF cellularmodel was a con-
sequence of the oxidative damage and not a direct effect of free iron. In
fact, the authors detected the rescue of the proteasome activity in the
presence of an anti-oxidant agent and not of an iron chelator
(Cozzi et al., 2010). Data obtained on Tgmice indicated that these aggre-
gates form lipofuscin that accumulates in lysosomes where the
degradation of ferritin occurs, leading to further release of redox-
active free iron (see Maccarinelli et al., 2014). Interestingly, it has been
described that lipofuscin itself may adsorb ferrous iron, thus constitut-
ing a redox-active surface that may catalyze the generation of hydroxyl
radicals and ampliﬁcation of the oxidative damage (Hohn and Grune,
2013). In the long run, lysosomes, congested by lipofuscin, may go
through rupture with consequent release of hydrolytic enzymes
and lipofuscin into cytosol (see Maccarinelli et al., 2014). Thus, both
proteasome and lysosomal cellular degradative systems result impaired
with the formation of aggregosomes in a self-maintained circle of
harmful events.
The other pathogenetic model proposed by (Muhoberac and Vidal,
2013) contemplated the gain of toxicity function of mutated ferritins
that easily precipitated, being surrounded by free iron. Indeed, Fe2+ has
a strong propensity to oxidation and precipitation at physiologic pH.
This may cause the non-speciﬁc precipitation of ferritin and other pro-
teins that further contribute to the formation of aggregates (Muhoberac
and Vidal, 2013).
However, it should be taken into account that the iron/ferritin
aggregates can be present in brain patients several years before the
developing of symptoms, as revealed by MRI analysis (Keogh et al.,
2012). In addition, they are present in extraneuronal tissues that do
not always show dysfunction (Curtis et al., 2001);(Mancuso et al.,
2005). Thus, the aggregates may be present in cells without giving
rise to an evident phenotype and neuronal cells appear to be the
most sensible cells to the pathogenetic mechanism. This suggests
that, even if the aggregates formation is a component of pathogenetic
mechanism, the main player in the NF pathogenesis is the alteration
of oxidative status, of which the brain tissue is particularly sensible
due to paucity of antioxidant-defenses of the neuronal cells. Thus,
the therapeutic intervention should be aimed not only at chelating
free iron but also at preventing the oxidative damage. Some attempts
to induce iron depletion have been undertaken on a few patients
by venesection; the treatment produced profound iron depletion
without yielding a clinical beneﬁt (Chinnery et al., 2007); (Kubota
et al., 2009).
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The overall data indicate that the different NF causative mutations
exert a similar outcome, impairing ferritin iron storage capacity. The
pathologic effect is compatible with the cell life, however, in long
term, the iron-dependent oxidative damage, particularly evident in
brain tissue, induces harmful effects. Thus, NF represents an exceptional
model to study the relationship between iron excess, oxidative stress
and neurodegeneration, a paradigm that exists in many neurodegener-
ative disorders. The full understanding of NF etiopathogenesis in human
is essential to deﬁne a rational approach that should allow, in the near
future, to design a trial for a disease modifying treatment. Moreover,
this knowledge can highlight common mechanisms in different
pathological neurodegenerative processes.
In addition, considering that the rate of lipofuscin accumulation is
reported to correlate negatively with longevity, elucidation of NF
pathogenetic mechanism can also help to explain mechanisms occurring
during the physiological process of aging.
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